Ribavirin

Ribavirin

Form: Capsules

Strength: 200 mg

Reference Brands: Rebetol®, Copegus®(EU & US)

Category: Anti Viral

Ribavirin Capsules 200 mg are oral antiviral medications used in the treatment of Chronic Hepatitis C, often in combination with interferon or direct-acting antivirals. Marketed globally under brands like Rebetol®, Copegus®, and Ribavin®, they help inhibit viral replication in HCV patients. Ribavirin is also considered in certain viral hemorrhagic fevers and RSV infections under physician guidance. Through PharmaB2B platforms, hospitals, importers, and procurement agencies can source WHO-GMP and USFDA-approved Ribavirin in bulk for tenders and national health programs. Trusted by clinicians for decades, Ribavirin remains a key component in combination antiviral therapies across global markets.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Zanamivir

Strength: 5 mg/blister

Form: Inhalation powder

Reference Brands: Relenza(EU & US)

View Details Get Enquiry
Oseltamivir Phosphate Capsule

Strength: Capsule- 30 mg, 45 mg, 75 mg; Oral Suspension - 6 mg/mL (reconstituted)

Form: Capsules and Oral solution

Reference Brands: Tamiflu(EU & US)

View Details Get Enquiry
Amantadine

Strength: Tab -100 mg; Capsule- 100 mg; Oral solution - 50 mg/5 mL; Extended-release capsule (ER) - 129 mg, 193 mg

Form: Tablet; Capsule; Oral Solution and ER Capsule

Reference Brands: Symmetrel(EU & US); Osmolex ER(US), Gocovri(US)

View Details Get Enquiry
Glecaprevir + Pibrentasvir

Strength: Glecaprevir- 100 mg + Pibrentasvir - 40 mg

Form: Tablet

Reference Brands: Mavyret (US); Maviret (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.